ahlam1399
08-04-2015, 08:13 PM
Regeneron raises Eylea sales forecast, shares at record
(Reuters) - Regeneron Inc's blockbuster eye drug, Eylea, showed ** signs of a slowdown as the drugmaker raised the full-year sales forecast for its flagship product above at least four analysts' expectation.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/48b33959/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=uQVMlgUx2mk:tUjNhXaLp-Q:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=uQVMlgUx2mk:tUjNhXaLp-Q:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=uQVMlgUx2mk:tUjNhXaLp-Q:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=uQVMlgUx2mk:tUjNhXaLp-Q:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=uQVMlgUx2mk:tUjNhXaLp-Q:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/uQVMlgUx2mk
(Reuters) - Regeneron Inc's blockbuster eye drug, Eylea, showed ** signs of a slowdown as the drugmaker raised the full-year sales forecast for its flagship product above at least four analysts' expectation.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/48b33959/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=uQVMlgUx2mk:tUjNhXaLp-Q:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=uQVMlgUx2mk:tUjNhXaLp-Q:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=uQVMlgUx2mk:tUjNhXaLp-Q:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=uQVMlgUx2mk:tUjNhXaLp-Q:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=uQVMlgUx2mk:tUjNhXaLp-Q:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/uQVMlgUx2mk